Weekly Paclitaxel and Carboplatin Dosing for Metastatic Cervical Cancer
For metastatic cervical cancer, the recommended weekly dosing regimen is paclitaxel 60 mg/m² IV over 1 hour followed by carboplatin AUC 2 IV over 30 minutes, administered weekly for 18 weeks (6 cycles of 3 weeks each). 1
Evidence-Based Dosing Regimen
The NCCN guidelines (2016) provide Category 1 evidence for this weekly regimen as a standard option for advanced cervical cancer 1. This dosing schedule delivers approximately 20 mg/m²/week of paclitaxel and maintains consistent platinum exposure while minimizing toxicity compared to every-3-week schedules.
Alternative Weekly Schedules
Research evidence supports two weekly approaches:
- Standard weekly: Paclitaxel 60 mg/m² + carboplatin AUC 2.7 weekly for 18 weeks 2
- Dose-dense: Paclitaxel 90 mg/m² + carboplatin AUC 4 on days 1 and 8 every 3 weeks 2
The dose-dense regimen showed higher response rates (58% vs 36%) but significantly more toxicity, including 12% febrile neutropenia versus 0% with the standard weekly schedule 2. For most patients, the standard weekly regimen (paclitaxel 60 mg/m² + carboplatin AUC 2) offers the best balance of efficacy and tolerability.
Clinical Context and Bevacizumab Consideration
While the question asks specifically about paclitaxel-carboplatin dosing, it's critical to note that current standard of care for metastatic cervical cancer includes bevacizumab based on GOG-240 trial results showing improved overall survival (16.8 vs 13.3 months, HR 0.765, p=0.0068) 3.
When bevacizumab is added, the typical regimen becomes:
- Paclitaxel 175 mg/m² IV over 3 hours
- Carboplatin AUC 5-6 IV
- Bevacizumab 15 mg/kg IV
- Given every 3 weeks for 6 cycles, then bevacizumab maintenance 3, 4
However, if bevacizumab is contraindicated (prior pelvic radiation with fistula risk, recent surgery, bleeding risk), the weekly paclitaxel-carboplatin regimen remains an excellent option 5.
Toxicity Management
Key toxicity differences between schedules:
- Weekly regimen: Lower rates of febrile neutropenia (0%), better tolerated in patients with prior radiation 2
- Every-3-week regimen: Higher hematologic toxicity, more neuropathy with cumulative dosing 1, 6
Critical safety consideration: Gastrointestinal perforation/fistula risk is 5-6% in patients with prior pelvic radiation when bevacizumab is used 5. The weekly carboplatin-paclitaxel regimen without bevacizumab may be preferred in this high-risk population.
Treatment Duration and Monitoring
- Standard duration: 18 weeks (6 three-week cycles with weekly dosing) 1
- Monitoring requirements: CBC before each weekly dose; hold treatment if neutrophils <1,500/mm³ or platelets <100,000/mm³ 7
- Dose modifications: Reduce by 20% for grade 3-4 neutropenia lasting >7 days or severe neuropathy 7
Performance Status Considerations
The weekly regimen is particularly appropriate for:
- Patients with prior chemotherapy exposure
- Those with borderline performance status
- Patients at high risk for neuropathy (diabetes, prior platinum exposure)
- Those with prior pelvic radiation (lower fistula risk without bevacizumab)
Recent data shows weekly paclitaxel-carboplatin achieved 79.7% overall response rate with median PFS of 11.3 months when combined with bevacizumab 5, and pembrolizumab combinations show similar efficacy across platinum choices (carboplatin vs cisplatin) 4.